| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoimmune Diseases | 15 | 2023 | 61 | 10.280 |
Why?
|
| Pemphigoid, Bullous | 16 | 2023 | 16 | 10.110 |
Why?
|
| Pemphigus | 21 | 2023 | 21 | 9.770 |
Why?
|
| Skin Diseases, Vesiculobullous | 8 | 2023 | 12 | 5.250 |
Why?
|
| Pneumonia, Pneumocystis | 7 | 2022 | 32 | 4.540 |
Why?
|
| Autoantibodies | 16 | 2023 | 100 | 3.990 |
Why?
|
| Skin Neoplasms | 10 | 2020 | 65 | 3.760 |
Why?
|
| Keratinocytes | 8 | 2021 | 12 | 3.580 |
Why?
|
| Melanoma | 7 | 2023 | 52 | 3.450 |
Why?
|
| Blister | 12 | 2023 | 13 | 2.870 |
Why?
|
| Psoriasis | 6 | 2023 | 11 | 2.790 |
Why?
|
| Humans | 83 | 2023 | 29337 | 2.550 |
Why?
|
| Cytokines | 4 | 2021 | 347 | 2.550 |
Why?
|
| Epidermolysis Bullosa Acquisita | 3 | 2023 | 3 | 2.420 |
Why?
|
| Immunosuppressive Agents | 5 | 2023 | 132 | 1.980 |
Why?
|
| Autoantigens | 8 | 2022 | 36 | 1.960 |
Why?
|
| Paraneoplastic Syndromes | 3 | 2018 | 8 | 1.850 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 3 | 2021 | 4 | 1.800 |
Why?
|
| Skin | 6 | 2023 | 117 | 1.790 |
Why?
|
| Epidermis | 3 | 2021 | 5 | 1.760 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 2021 | 7 | 1.600 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 38 | 1.570 |
Why?
|
| Eosinophils | 3 | 2020 | 47 | 1.560 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 3 | 2020 | 9 | 1.390 |
Why?
|
| Students, Medical | 3 | 2014 | 46 | 1.370 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 129 | 1.300 |
Why?
|
| Pneumocystis carinii | 2 | 2017 | 2 | 1.230 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2021 | 3 | 1.160 |
Why?
|
| Internet | 3 | 2016 | 91 | 1.090 |
Why?
|
| Fibromyalgia | 3 | 2014 | 29 | 1.040 |
Why?
|
| Radiodermatitis | 2 | 2015 | 2 | 1.020 |
Why?
|
| Antioxidants | 2 | 2015 | 56 | 0.970 |
Why?
|
| Drug Industry | 2 | 2014 | 28 | 0.940 |
Why?
|
| Biological Products | 2 | 2021 | 40 | 0.940 |
Why?
|
| Physician-Patient Relations | 2 | 2014 | 39 | 0.930 |
Why?
|
| Skin Abnormalities | 1 | 2023 | 2 | 0.930 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 9 | 0.930 |
Why?
|
| Chemokine CCL11 | 2 | 2019 | 8 | 0.880 |
Why?
|
| Laminin | 2 | 2021 | 8 | 0.860 |
Why?
|
| Rituximab | 6 | 2023 | 53 | 0.850 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2022 | 16 | 0.840 |
Why?
|
| Software | 3 | 2020 | 72 | 0.830 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 40 | 0.830 |
Why?
|
| Animals | 12 | 2023 | 4552 | 0.820 |
Why?
|
| Glucocorticoids | 2 | 2019 | 67 | 0.810 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 83 | 0.800 |
Why?
|
| Epitopes | 3 | 2018 | 81 | 0.800 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2020 | 358 | 0.790 |
Why?
|
| Pemphigoid Gestationis | 1 | 2020 | 1 | 0.770 |
Why?
|
| Dermatology | 1 | 2020 | 6 | 0.770 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2017 | 18 | 0.760 |
Why?
|
| Skin Diseases | 1 | 2020 | 26 | 0.760 |
Why?
|
| Dermatologic Agents | 2 | 2020 | 8 | 0.760 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2017 | 42 | 0.750 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 19 | 0.730 |
Why?
|
| Biological Factors | 1 | 2019 | 9 | 0.730 |
Why?
|
| Chemokine CCL26 | 1 | 2019 | 2 | 0.720 |
Why?
|
| Chemokine CCL24 | 1 | 2019 | 2 | 0.720 |
Why?
|
| Dermatitis | 1 | 2019 | 3 | 0.720 |
Why?
|
| Female | 22 | 2021 | 16197 | 0.700 |
Why?
|
| Middle Aged | 17 | 2021 | 9823 | 0.700 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2019 | 10 | 0.690 |
Why?
|
| Body Fluids | 1 | 2019 | 19 | 0.690 |
Why?
|
| Search Engine | 2 | 2016 | 5 | 0.690 |
Why?
|
| Eosinophilia | 1 | 2019 | 47 | 0.690 |
Why?
|
| Colitis, Ulcerative | 1 | 2019 | 66 | 0.690 |
Why?
|
| Immunologic Factors | 4 | 2022 | 39 | 0.690 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 46 | 0.680 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 2018 | 1 | 0.680 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2018 | 2 | 0.680 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 30 | 0.680 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 219 | 0.670 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 63 | 0.670 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2018 | 6 | 0.670 |
Why?
|
| Pemphigus, Benign Familial | 1 | 2018 | 1 | 0.670 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 22 | 0.660 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 31 | 0.660 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2018 | 3 | 0.660 |
Why?
|
| Desmoglein 3 | 4 | 2020 | 4 | 0.660 |
Why?
|
| Leg Dermatoses | 1 | 2018 | 1 | 0.650 |
Why?
|
| Basement Membrane | 1 | 2018 | 12 | 0.650 |
Why?
|
| Neoplasms | 3 | 2018 | 247 | 0.640 |
Why?
|
| Insurance Carriers | 1 | 2017 | 2 | 0.640 |
Why?
|
| Mucous Membrane | 1 | 2018 | 40 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 333 | 0.630 |
Why?
|
| Insurance, Health | 2 | 2015 | 22 | 0.620 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2015 | 10 | 0.620 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 52 | 0.610 |
Why?
|
| Incidence | 7 | 2020 | 756 | 0.610 |
Why?
|
| Vulvar Neoplasms | 1 | 2017 | 3 | 0.600 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2017 | 2 | 0.600 |
Why?
|
| Triazines | 1 | 2017 | 10 | 0.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 113 | 0.600 |
Why?
|
| Exanthema | 1 | 2017 | 15 | 0.590 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2015 | 4 | 0.590 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2013 | 30 | 0.590 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 6 | 0.570 |
Why?
|
| Anticonvulsants | 1 | 2017 | 109 | 0.560 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2015 | 10 | 0.550 |
Why?
|
| Hematoma | 1 | 2015 | 19 | 0.550 |
Why?
|
| Cephalexin | 1 | 2015 | 1 | 0.550 |
Why?
|
| Private Sector | 1 | 2015 | 1 | 0.550 |
Why?
|
| Colitis | 1 | 2015 | 37 | 0.550 |
Why?
|
| Plasmapheresis | 1 | 2015 | 14 | 0.540 |
Why?
|
| Colorimetry | 1 | 2015 | 2 | 0.540 |
Why?
|
| Melanins | 1 | 2015 | 11 | 0.540 |
Why?
|
| Drug Costs | 1 | 2015 | 17 | 0.540 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2015 | 11 | 0.540 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 4851 | 0.540 |
Why?
|
| Castleman Disease | 1 | 2015 | 1 | 0.540 |
Why?
|
| Insurance Coverage | 1 | 2015 | 13 | 0.540 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2015 | 4 | 0.530 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 7 | 0.520 |
Why?
|
| Risk Factors | 8 | 2021 | 2443 | 0.520 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 78 | 0.510 |
Why?
|
| Health Education | 1 | 2014 | 39 | 0.500 |
Why?
|
| Kidney | 1 | 2015 | 173 | 0.500 |
Why?
|
| Argyria | 1 | 2014 | 1 | 0.500 |
Why?
|
| Cyanosis | 1 | 2014 | 1 | 0.500 |
Why?
|
| Silver | 1 | 2014 | 4 | 0.490 |
Why?
|
| Truth Disclosure | 1 | 2014 | 8 | 0.490 |
Why?
|
| Ethics, Pharmacy | 1 | 2013 | 1 | 0.490 |
Why?
|
| Motion Pictures | 1 | 2013 | 4 | 0.490 |
Why?
|
| Liability, Legal | 1 | 2013 | 7 | 0.490 |
Why?
|
| Fluoroscopy | 1 | 2014 | 52 | 0.480 |
Why?
|
| Conflict of Interest | 1 | 2014 | 18 | 0.480 |
Why?
|
| Mice | 6 | 2023 | 1607 | 0.480 |
Why?
|
| Male | 17 | 2021 | 15621 | 0.470 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 81 | 0.460 |
Why?
|
| Empathy | 1 | 2013 | 35 | 0.460 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 63 | 0.460 |
Why?
|
| Merkel cell polyomavirus | 1 | 2013 | 1 | 0.460 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 178 | 0.460 |
Why?
|
| Tumor Virus Infections | 1 | 2013 | 15 | 0.450 |
Why?
|
| Polyomavirus Infections | 1 | 2013 | 22 | 0.450 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 53 | 0.450 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 90 | 0.440 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 211 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 132 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 194 | 0.440 |
Why?
|
| Complement System Proteins | 2 | 2022 | 15 | 0.430 |
Why?
|
| Herpes Labialis | 1 | 2011 | 2 | 0.420 |
Why?
|
| Acyclovir | 1 | 2011 | 5 | 0.420 |
Why?
|
| Vestibular Neuronitis | 1 | 2011 | 3 | 0.420 |
Why?
|
| Valine | 1 | 2011 | 11 | 0.420 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 153 | 0.390 |
Why?
|
| Dermatitis, Atopic | 2 | 2021 | 19 | 0.390 |
Why?
|
| Hidradenitis Suppurativa | 2 | 2020 | 3 | 0.380 |
Why?
|
| Antiviral Agents | 1 | 2011 | 132 | 0.370 |
Why?
|
| United States | 6 | 2017 | 2333 | 0.370 |
Why?
|
| Interleukin-5 | 2 | 2020 | 10 | 0.360 |
Why?
|
| Prevalence | 6 | 2021 | 487 | 0.360 |
Why?
|
| Aged | 9 | 2021 | 9448 | 0.360 |
Why?
|
| Administration, Topical | 2 | 2020 | 17 | 0.350 |
Why?
|
| Administration, Oral | 2 | 2020 | 140 | 0.340 |
Why?
|
| Adult | 8 | 2021 | 8601 | 0.340 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 391 | 0.330 |
Why?
|
| Immunoglobulin E | 2 | 2020 | 15 | 0.330 |
Why?
|
| Pregnancy | 2 | 2020 | 403 | 0.320 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3273 | 0.310 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 340 | 0.280 |
Why?
|
| Recurrence | 2 | 2019 | 350 | 0.260 |
Why?
|
| Interleukin-13 | 1 | 2023 | 10 | 0.240 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 959 | 0.240 |
Why?
|
| Interleukin-23 | 1 | 2023 | 12 | 0.240 |
Why?
|
| Immunotherapy | 1 | 2023 | 62 | 0.230 |
Why?
|
| Up-Regulation | 2 | 2021 | 174 | 0.230 |
Why?
|
| Child | 3 | 2020 | 1346 | 0.230 |
Why?
|
| Atrophy | 1 | 2023 | 102 | 0.230 |
Why?
|
| Leg | 1 | 2023 | 49 | 0.230 |
Why?
|
| Neutrophils | 1 | 2023 | 117 | 0.220 |
Why?
|
| Age of Onset | 2 | 2020 | 108 | 0.220 |
Why?
|
| Treatment Outcome | 3 | 2020 | 3478 | 0.220 |
Why?
|
| Podocytes | 1 | 2023 | 85 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 79 | 0.210 |
Why?
|
| Immunogenetics | 1 | 2022 | 2 | 0.210 |
Why?
|
| Antibody Specificity | 1 | 2021 | 50 | 0.210 |
Why?
|
| Pyridines | 1 | 2021 | 42 | 0.210 |
Why?
|
| Eosinophil Major Basic Protein | 1 | 2021 | 1 | 0.210 |
Why?
|
| Peroxidases | 1 | 2021 | 7 | 0.210 |
Why?
|
| Galectins | 1 | 2021 | 6 | 0.200 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 24 | 0.200 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 26 | 0.200 |
Why?
|
| Adolescent | 3 | 2020 | 2279 | 0.200 |
Why?
|
| Transcriptome | 1 | 2021 | 83 | 0.200 |
Why?
|
| Glycoproteins | 1 | 2021 | 58 | 0.200 |
Why?
|
| Proteome | 1 | 2021 | 39 | 0.200 |
Why?
|
| Young Adult | 3 | 2020 | 1932 | 0.200 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2020 | 3 | 0.200 |
Why?
|
| Interleukin-4 | 1 | 2021 | 35 | 0.200 |
Why?
|
| Piperazines | 1 | 2021 | 90 | 0.200 |
Why?
|
| Immunity | 1 | 2020 | 24 | 0.200 |
Why?
|
| Acne Keloid | 1 | 2020 | 1 | 0.190 |
Why?
|
| MicroRNAs | 1 | 2021 | 42 | 0.190 |
Why?
|
| Proteomics | 1 | 2021 | 91 | 0.190 |
Why?
|
| Drug Resistance | 1 | 2020 | 55 | 0.190 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 80 | 0.190 |
Why?
|
| Lymphocytes | 1 | 2020 | 110 | 0.190 |
Why?
|
| Israel | 4 | 2021 | 16 | 0.190 |
Why?
|
| Paraffin Embedding | 1 | 2020 | 3 | 0.190 |
Why?
|
| Cells, Cultured | 1 | 2021 | 676 | 0.180 |
Why?
|
| Workflow | 1 | 2020 | 13 | 0.180 |
Why?
|
| Consensus | 1 | 2020 | 105 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2020 | 679 | 0.180 |
Why?
|
| Biopsy | 2 | 2018 | 234 | 0.180 |
Why?
|
| Wound Healing | 1 | 2020 | 168 | 0.180 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 724 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 100 | 0.180 |
Why?
|
| Dapsone | 1 | 2019 | 3 | 0.180 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 301 | 0.180 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2019 | 7 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 175 | 0.180 |
Why?
|
| Birds | 1 | 2019 | 7 | 0.180 |
Why?
|
| Desmoglein 1 | 1 | 2019 | 1 | 0.170 |
Why?
|
| Chemokines | 1 | 2019 | 29 | 0.170 |
Why?
|
| SEER Program | 2 | 2016 | 38 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 12 | 0.170 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 17 | 0.170 |
Why?
|
| Chemoprevention | 1 | 2018 | 5 | 0.170 |
Why?
|
| Interleukin-17 | 1 | 2018 | 27 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 59 | 0.170 |
Why?
|
| Interleukins | 1 | 2018 | 37 | 0.170 |
Why?
|
| Desmosomes | 1 | 2018 | 1 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 215 | 0.170 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2018 | 4 | 0.170 |
Why?
|
| Infant | 2 | 2020 | 531 | 0.170 |
Why?
|
| Cell Survival | 1 | 2018 | 169 | 0.160 |
Why?
|
| Clobetasol | 1 | 2018 | 1 | 0.160 |
Why?
|
| Collagen Type VII | 1 | 2018 | 1 | 0.160 |
Why?
|
| Child, Preschool | 2 | 2020 | 642 | 0.160 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 125 | 0.160 |
Why?
|
| Cell Line | 1 | 2018 | 298 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2020 | 604 | 0.160 |
Why?
|
| Mycosis Fungoides | 1 | 2017 | 6 | 0.160 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2017 | 3 | 0.160 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 248 | 0.160 |
Why?
|
| Crohn Disease | 2 | 2018 | 46 | 0.160 |
Why?
|
| Chickens | 1 | 2017 | 20 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 101 | 0.160 |
Why?
|
| Arthritis | 1 | 2018 | 107 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 81 | 0.160 |
Why?
|
| Prednisone | 1 | 2018 | 67 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 107 | 0.160 |
Why?
|
| Population Surveillance | 1 | 2018 | 116 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 241 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2019 | 495 | 0.150 |
Why?
|
| Apoptosis | 1 | 2018 | 251 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 389 | 0.150 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 88 | 0.150 |
Why?
|
| Calcium | 1 | 2021 | 491 | 0.150 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 284 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 45 | 0.140 |
Why?
|
| Ki-1 Antigen | 1 | 2016 | 2 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2015 | 59 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 218 | 0.140 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 4 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1113 | 0.140 |
Why?
|
| Platelet Count | 1 | 2015 | 20 | 0.140 |
Why?
|
| Colonoscopy | 1 | 2015 | 51 | 0.140 |
Why?
|
| Skin Care | 1 | 2015 | 14 | 0.140 |
Why?
|
| Policy Making | 1 | 2015 | 15 | 0.140 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2015 | 13 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2015 | 47 | 0.130 |
Why?
|
| Risk | 1 | 2016 | 217 | 0.130 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 10 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 88 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 200 | 0.130 |
Why?
|
| Bathing Beaches | 1 | 2014 | 1 | 0.130 |
Why?
|
| Evaluation Studies as Topic | 1 | 2015 | 56 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 340 | 0.130 |
Why?
|
| Photography | 1 | 2014 | 17 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 1830 | 0.130 |
Why?
|
| Time Factors | 2 | 2017 | 1616 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2015 | 70 | 0.130 |
Why?
|
| Hospitalization | 1 | 2017 | 317 | 0.130 |
Why?
|
| Phenotype | 1 | 2015 | 355 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 77 | 0.130 |
Why?
|
| Sex Factors | 1 | 2016 | 496 | 0.120 |
Why?
|
| Hypogonadism | 1 | 2014 | 6 | 0.120 |
Why?
|
| Acantholysis | 1 | 2013 | 1 | 0.120 |
Why?
|
| Malpractice | 1 | 2013 | 10 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2013 | 17 | 0.120 |
Why?
|
| Mental Health | 1 | 2015 | 105 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2015 | 330 | 0.120 |
Why?
|
| Injections, Intra-Articular | 1 | 2014 | 88 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 31 | 0.120 |
Why?
|
| Sucralfate | 1 | 2013 | 3 | 0.120 |
Why?
|
| Polyphenols | 1 | 2013 | 5 | 0.120 |
Why?
|
| Pentoxifylline | 1 | 2013 | 7 | 0.120 |
Why?
|
| Free Radical Scavengers | 1 | 2013 | 12 | 0.120 |
Why?
|
| Television | 1 | 2013 | 6 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 78 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 100 | 0.120 |
Why?
|
| Ascorbic Acid | 1 | 2013 | 32 | 0.120 |
Why?
|
| Erectile Dysfunction | 1 | 2014 | 46 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2013 | 50 | 0.110 |
Why?
|
| Neuroma, Acoustic | 1 | 2013 | 10 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2013 | 146 | 0.110 |
Why?
|
| Age Factors | 1 | 2016 | 843 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 34 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2013 | 33 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 208 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2014 | 138 | 0.110 |
Why?
|
| Vertigo | 1 | 2011 | 8 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 788 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 770 | 0.100 |
Why?
|
| Prognosis | 1 | 2013 | 840 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 1184 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2015 | 957 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 498 | 0.080 |
Why?
|
| Shoulder Joint | 1 | 2014 | 572 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2023 | 1939 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2021 | 482 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1442 | 0.070 |
Why?
|
| Integrins | 1 | 2023 | 19 | 0.060 |
Why?
|
| Azathioprine | 1 | 2023 | 9 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2023 | 8 | 0.060 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 41 | 0.060 |
Why?
|
| Proteinuria | 1 | 2023 | 81 | 0.060 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 12 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 340 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2019 | 9 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2019 | 55 | 0.040 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2019 | 22 | 0.040 |
Why?
|
| Smoking | 1 | 2020 | 194 | 0.040 |
Why?
|
| Hashimoto Disease | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 263 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 75 | 0.040 |
Why?
|
| Biomarkers | 1 | 2021 | 689 | 0.040 |
Why?
|
| Desmogleins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Immune Sera | 1 | 2015 | 9 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 47 | 0.030 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 4 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 86 | 0.030 |
Why?
|
| Queensland | 1 | 2015 | 1 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 44 | 0.030 |
Why?
|
| Commerce | 1 | 2015 | 13 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 96 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 94 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 87 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 260 | 0.030 |
Why?
|
| Mutation | 1 | 2015 | 383 | 0.030 |
Why?
|
| Petrous Bone | 1 | 2013 | 7 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 441 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 787 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1221 | 0.020 |
Why?
|